// App-Quantinova.ai

e14531 : CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.

Researchers

Presenter

  • Lincy Chu

Principal Investigators

  • Amanda K. L. Anderson

  • Mark Andrew Landers

  • Yipeng Wang

  • Mark R. Kelley

  • Richard Adam Messmann

Medical Centers

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Indiana University School of Medicine, Indianapolis, IN

  • Apexian Pharmaceuticals, Indianapolis, IN

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • Circulating tumor cells

Drug/Treatment

  • E-3330

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT0337508

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved